Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 8

Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole

Authors Corcia P, Gordon PH

Published Date August 2012 Volume 2012:8 Pages 359—366


Received 20 July 2012, Accepted 1 August 2012, Published 27 August 2012

Philippe Corcia,1 Paul H Gordon2

Centre SLA, CHRU de Tours, Tours, France; UMR INSERM U930, Université François Rabelais de Tours (PC), Tours, France; 2AP-HP, Hôpital de la Pitié-Salpêtrière, Département des Maladies du Système Nerveux (PHG), Paris, France

Abstract: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that leads to progressive weakness from loss of motor neurons and death on average in less than 3 years after symptom onset. No clear causes have been found and just one medication, riluzole, extends survival. Researchers have identified some of the cellular processes that occur after disease onset, including mitochondrial dysfunction, protein aggregation, oxidative stress, excitotoxicity, inflammation, and apoptosis. Mitochondrial disease may be a primary event in neurodegeneration or occur secondary to other cellular processes, and may itself contribute to oxidative stress, excitotoxicity, and apoptosis. Clinical trials currently aim to slow disease progression by testing drugs that impact one or more of these pathways. While every agent tested in the 18 years after the approval of riluzole has been ineffective, basic and clinical research methods in ALS have become dramatically more sophisticated. Dexpramipexole (RPPX), the R(+) enantiomer of pramiprexole, which is approved for symptomatic treatment of Parkinson disease, carries perhaps the currently largest body of pre- and early clinical data that support testing in ALS. The neuroprotective properties of RPPX in various models of neurodegeneration, including the ALS murine model, may be produced through protective actions on mitochondria. Early phase trials in human ALS suggest that the drug can be taken safely by patients in doses that provide neuroprotection in preclinical models. A Phase III trial to test the efficacy of RPPX in ALS is underway.

Keywords: dexpramipexole, amyotrophic lateral sclerosis, survival, clinical trials, neurodegeneration

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Importance and management of micronutrient deficiencies in patients with Alzheimer’s disease

Cardoso BR, Cominetti C, Cozzolino SMF

Clinical Interventions in Aging 2013, 8:531-542

Published Date: 10 May 2013

Skin-protective effects of a zinc oxide-functionalized textile and its relevance for atopic dermatitis

Wiegand C, Hipler U-C, Boldt S, Strehle J, Wollina U

Clinical, Cosmetic and Investigational Dermatology 2013, 6:115-121

Published Date: 6 May 2013

Age-related changes in the joint position sense of the human hand

Kalisch T, Kattenstroth JC, Kowalewski R, Tegenthoff M, Dinse HR

Clinical Interventions in Aging 2012, 7:499-507

Published Date: 22 November 2012

Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer’s disease models

Bernardi A, Frozza RL, Meneghetti A, Hoppe JB, Battastini AMO, Pohlmann AR, Guterres SS, Salbego CG

International Journal of Nanomedicine 2012, 7:4927-4942

Published Date: 13 September 2012

A causative link between periodontal disease and glomerulonephritis: a preliminary study

Mohammad Reza Ardalan, Kamyar Ghabili, Reza Pourabbas, et al

Therapeutics and Clinical Risk Management 2011, 7:93-98

Published Date: 8 March 2011

Meconial peritrophic matrix and meconial degradation in the biting midge, Culicoides variipennis (Coquillett) (Diptera: Ceratopogonidae)

Luis Renato León Villalba, William S Romoser, Lisa Patrican

Open Access Insect Physiology 2011, 3:1-6

Published Date: 10 February 2011

Artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria

Stephan Ehrhardt, Christian G Meyer

Therapeutics and Clinical Risk Management 2009, 5:805-815

Published Date: 6 October 2009

Anatomical and molecular imaging of skin cancer

Hao Hong, Jiangtao Sun, Weibo Cai

Clinical, Cosmetic and Investigational Dermatology 2008, 1:1-17

Published Date: 7 October 2008